Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma Aids's Operating Income for the
three
months ended in Mar. 2026 was BDT26.2 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was BDT105.7 Mil.
Operating Margin % is calculated as Operating Income divided by its Revenue. Pharma Aids's Operating Income for the
three
months ended in Mar. 2026 was BDT26.2 Mil. Pharma Aids's Revenue for the
three
months ended in Mar. 2026 was BDT123.3 Mil. Therefore, Pharma Aids's Operating Margin % for the quarter that ended in Mar. 2026 was 21.29%.
Warning Sign:
Pharma Aids Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -9.9%.
Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Pharma Aids's annualizedROC % for the quarter that ended in Mar. 2026 was 15.34%.
Pharma Aids's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 24.24%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.
Be Aware
Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Pharma Aids Operating Income Related Terms
Pharma Aids Operating Income Historical Data
* Premium members only.
The historical data trend for Pharma Aids's Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.
Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT105.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Income of BDT105.7 Mil mean?
Pharma Aids (DHA:PHARMAID) has a Operating Income of BDT105.7 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Pharma Aids and its competitors.
Is Pharma Aids' Operating Income too high?
Pharma Aids' current Operating Income is BDT105.7 Mil. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' Operating Income compare to ISRG and BDX?
Pharma Aids' Operating Income of BDT105.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Medical Devices & Instruments company?
A good Operating Income depends on the Medical Devices & Instruments industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Pharma Aids and its competitors. Pharma Aids's current Operating Income is BDT105.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT764.97, compared to a current price of BDT624.60 — trading 18.3% below its estimated fair value. The current Operating Income is BDT105.7 Mil. Pharma Aids' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current Operating Income is BDT105.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued.
The current stock price of BDT624.60 is trading 18.3% below its estimated GF Value™ of BDT764.97.
GuruFocus considers Pharma Aids to be Modestly Undervalued.
Key valuation signals for DHA:PHARMAID:
Operating Income: BDT105.7 Mil
GF Value™: BDT764.97 vs. price of BDT624.60 (18.3% below fair value)
No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score
Get the complete analysis for DHA:PHARMAID
Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:PHARMAID has been successfully added to your 
